ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,370 GBX | +0.31% |
|
+2.66% | +16.70% |
| 02:25pm | Pfizer and AstraZeneca announce new investments of nearly $1 billion in France | RE |
| May. 08 | AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 51.34B | Sales 2025 * | 55.01B | Capitalization | 240B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.62B | Net income 2025 * | 10.29B | EV / Sales 2024 * | 5.07 x |
| Net Debt 2024 * | 20.53B | Net Debt 2025 * | 13.65B | EV / Sales 2025 * | 4.61 x |
| P/E ratio 2024 * |
28.3
x | P/E ratio 2025 * |
23.5
x | Employees | 89,900 |
| Yield 2024 * |
1.98% | Yield 2025 * |
2.09% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | +0.31% | ||
| 1 week | +2.66% | ||
| Current month | +2.55% | ||
| 1 month | +12.84% | ||
| 3 months | +26.73% | ||
| 6 months | +22.60% | ||
| Current year | +16.70% |
1 week
11 966.00
12 442.00
1 month
10 764.0012 488.00
Current year
9 461.0012 488.00
1 year
9 461.0012 488.00
3 years
7 700.0012 488.00
5 years
5 642.0012 488.00
10 years
3 680.0012 488.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 0 M€ | +16.95% | ||
| 5.17% | 0 M€ | +7.69% | - | |
| 4.89% | 0 M€ | +12.94% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 12,370 | +0.31% | 1,408,188 |
| 24-05-09 | 12,332 | +0.55% | 1,329,958 |
| 24-05-08 | 12,264 | +1.20% | 2,091,841 |
| 24-05-07 | 12,118 | +0.56% | 2,562,233 |
| 24-05-03 | 12,050 | -0.87% | 1,642,783 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
154.8
USD
Average target price
166.5
USD
Spread / Average Target
+7.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.70% | 240B | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B | |
| -2.71% | 159B |
- Stock Market
- Equities
- AZN Stock